Barbara Weber - 10 Aug 2021 Form 3 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
By: /s/ Daniella Beckman, as attorney-in-fact
Issuer symbol
TNGX
Transactions as of
10 Aug 2021
Net transactions value
$0
Form type
3
Filing time
12 Aug 2021, 20:42:44 UTC
Previous filing
24 Jun 2021
Next filing
16 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TNGX Common Stock 1,367,592 10 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TNGX Stock Option (Right to Buy) 10 Aug 2021 Common Stock 219,164 $1.53 Direct F1
holding TNGX Stock Option (Right to Buy) 10 Aug 2021 Common Stock 219,164 $1.65 Direct F2
holding TNGX Stock Option (Right to Buy) 10 Aug 2021 Common Stock 1,284,137 $3.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in equally monthly installments over a period of 48 months from January 1, 2019.
F2 This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2020.
F3 This option shall vest and become exercisable in monthly installments over a period of 48 months from January 1, 2021.

Remarks:

Exhibit 24: Power of Attorney